1. Introduction {#s0005}
===============

Sickle cell disease (SCD) is a chronic hereditary disease not only in the developing countries but also in the developed world. There are more than 500,000 newly diagnosed infants, and about 200,000 people with sickle cell anaemia per year, according to the World Health Organization ([@b0005], [@b0090], [@b0010]),

Genetic blood diseases including SCD and thalessemia are caused by molecular changes in specific blood proteins called globins. Haemoglobin (Hb) is made up of four chains of globin, each of which carries the heme group, which is associated with oxygen ([@b0020]). SCD is one of the most common and aggressive red blood cell (RBC) disorders, and is caused by abnormal haemoglobin known as HbS ([@b0015]). SCD results from a substitution of adenine (A) to thymine (T) in 6th codon of β-globin. SCD is featured by many signs such as: inflammation, stroke, chronic haemolysis, and acute chest pain. Abnormal RBC shape causing them to lose their flexibility and turn into the form of solid sickles ([@b0025]).

In Saudi Arabia, SCD was first identified in the eastern region in 1960 by Lehman (1963), which leads to many subsequent studies at the regional and national level to determine the clinical and genetic background of SCD. In Saudi Arabia, SCD is a relatively common hereditary disorder, ranging from 0.4 to 8% while SCD carriers ranged from 2% to 27%. These estimates do not include neonatal screening, which may increase the real frequency of the disease ([@b0040]).

There are more than three million people had these genetic blood diseases in the Saudi Arabia, of which 30% in the Eastern Region ([@b0100]). El-Hazmi and others demonsated two different types of sickle cell anaemia, the average type dominated in the eastern region, while the severe type observed in most patients in the south western region ([@b0055], [@b0060], [@b0070], [@b0110], [@b0080], [@b0065], [@b0115], [@b0075], [@b0095]).

The aim was to study the molecular survey of locus control regions (LCR) in Saudi patients with sickle cell anemia, and to identify the genetic variables and their clinical manifestations.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

The study was conducted on 69 of sickle cell anemia patients selected randomly from the attending the blood diseases clinic at King Khalid University Hospital (KKUH, Riyadh, KSA) from different regions of Saudi Arabia between June2017--June2019. Hematological and biochemical measurements and history of each patient were investigated. The study protocol respected the most recent Declaration of Helsinki, written informed consent and Research Ethics Committee approval were obtained from all cases.

2.2. Sample {#s0020}
-----------

10 ml of venous blood was withdrawn from each patient and distributed to two tubes (each containing 5 ml) of ethylenediamine tetra acetic acid (EDTA).

2.3. Extraction of DNA {#s0025}
----------------------

DNA was extracted using Qiagen DNA extraction kit, according to the approved protocol by GentraPuregene Handbook 09/2007.

2.4. Primers & PCR {#s0030}
------------------

Primers were designed, requested and obtained through the Oligo ordering online. PCR primers were used (see [Table 1](#t0005){ref-type="table"}).). Thirty-five cycles of PCR, with denaturation at 94o C for 30 s, annealing at 60o C for 1 min, and extension at 72o C for 1 min, were performed on a programmed-temperature system (Hybaid OmniGene; Midwest Scientific, Missouri, United States). After PCR amplification, 10 µl of the PCR products were mixed with 2 µl DNA loading buffer and electrophoresed on a 2 percent agarose gel containing 0.2 µg/ml ethidium bromide in 0.5X TBE buffer. A DNA ladder was also run in parallel. The amplified gel was visualized and photographed under UV light (Bio-Rad Gel Doc 2000 Imaging System).Table 1The primers that were designed and used in this study to multiply the LCR.PrimerPrimer seq 5′ -- 3′Product size (b.p)LCR-1FCCTGCAAGTTATCTGGTCAC445LCR-1RCTTAGGGGCTTATTTTATTTTGTLCR-2FCAGGGCAGATGGCAAAAA460LCR-2RCTGACCCCGTATGTGAGCALCR-3FATGGGGCAATGAAGCAAAGGAA595LCR-3RACCCATACATAGGAAGCCCATAGCLCR-5FGCAAACACAGCAAACACAACGAC442LCR-5RATGGCAGAGGCAGAGGACAGGTTGLCR-6FTTCCCAAAACCTAATAAGTAAC520LCR-6RCCTCAGCCCTCCCTCTAALCR-7FTGCCCTGGCCCACAAGTATC539LCR-7RTCAGGGGAAAGGTGGTATCTCTAA

2.5. Statistical analysis {#s0035}
-------------------------

The data obtained was subjected to a statistical analysis using Window Excel and SPSS v17 statistical tools. ANOVAs tests for multiple comparisons and significant analysis (p \< 0.05) were carried out.

3. Results {#s0040}
==========

The study was conducted on 69 patients with sickle cell anemia from the outpatient clinic of blood diseases at the KKUH from different regions of Saudi Arabia.

In this study, locus control region of HBB was identified and propagated using the primers designed in [Table 1](#t0005){ref-type="table"}. The analysis of the nucleotide sequencing for the entire LCR segment except the LCR4 was determined for study samples. These changes were widely varied between substitution at different nitrogen bases. Changes were found either homo or asymmetric. The number of changes also was identified in the control zones, was 69. The first zone of the control areas of the LCR-HBB / F1 gene begins at the number 668 of chromosome 11 and ends at 1110 and is called the LCR-HS1 region. Twenty changes have been detected in this area. The highest percentage in this region, are shown by all sample at 100%, while the lowest rate was 1.3% in twelve changes in the region in one patient only. The changes are shown in [Table 2](#t0010){ref-type="table"}.Table 2Hematological and biochemical measurements from SCA patients.WBCHgbPltBilirubinLDHMean921136848446SD23516639206

3.1. Clinical and blood data in the research sample {#s0045}
---------------------------------------------------

[Table 3](#t0015){ref-type="table"} presents a summary of hematological and biochemical measurements from SCD patients who have been followed for more than 4 years.Table 3Distrubution of LCR changes per base per sample.LCR-HBB/F1\
start at 668\
end at 1110\
LCR--HS1Region/FragmentBase changeN.SamplesPercent %1749--750 -/t homo ins.11.3%2751--752 -/c homo ins.79.1%3752--753 -/c homo ins.11.3%4752--753 -/t homo ins.11.3%5753--756 - -/ct homo ins.11.3%6754--657 - -/tt homo ins.22.6%7757--759 -/c homo ins.11.3%8765--767 -/t homo ins.22.6%9765--767 -/c homo ins.11.3%10805--807 -/c homo ins.79.1%11805--807 -/t homo ins.11.3%12704 -\>T homo ins.11.3%13710 A\>- homo del.1316.9%14718--720 -\>T homo ins.11.3%15789 G \> A het.22.6%16797 G \> A het.11.3%17817--819 -\>t homo ins.11.3%18907 G \> A het.11.3%19963 A \> G homo.4963.6%201032 G \> A het.77100.0%LCR-HBB/F2\
start at 4397\
end at 4991\
LCR--HS214575 G \> A het.77100.0%24631 G \> A het.77100.0%34673 G \> A het.77100.0%44950--4951 -\>C homo ins.22.6%54455--4456 \--\>TC homo ins.11.3%64562 G \> A het.45.2%LCR-HBB/F3\
start at 8757\
end at 9219\
LCR--HS318874 G \> A het.79.1%28899to 8902 TATA\>\-\-\-- homo del.11.3%38900to 8902 TA\>\-\-\-- homo del.11.3%48906--8910 \-- \> CA homo ins.11.3%58912 G \> A het.56.5%68914 A \> G homo.4254.5%78915to 8920 TATA\>\-\-\-- homo del.4254.5%88921to 8922 \--\> AT homo ins.1013.0%98947 A \> T het.2228.6%108948 A \> T het.77100.0%118957 G \> A het.77100.0%  Region/FragmentBase changeN.SamplesPercent %LCR-HBB/F4\
start at 8757\
end at 9219\
LCR--HS3128960 T \> A het.1823.4%138966G \> T homo.7698.7%148969 A \> T het.79.1%158977 T \> A het.1823.4%168994 A \> G homo.77100.0%178997 T \> G homo.6989.6%188997 T \> G het.810.4%199009C \> A het.2532.5%209012 G \> A het.77100.0%219021 G \> A het.77100.0%LCR-HBB/F5\
start at 34,273\
end at 34,816\
G--promoter\
region134,502 G \> A het.11.3%234,662C \> A het.4558.4%334,663C \> A het.4558.4%434,687C \> T het.1519.5%  Region/FragmentBase changeN.SamplesPercent %LCR-HBB/F6\
start at 61,441\
end at 61,961\
(AT)x(T)y region161,495 to 61,496 -\>C homo ins.11.3%261,522 to 6523 -\>A homo ins.11.3%361,558 to 6559 -\>A homo ins.22.6%461586 T \> C homo.22.6%561,586 - - \> CA homo ins.33.9%661590 T \> C homo.22.6%761,593C \> T homo.810.4%861,594 - - \>AT homo ins.911.7%  Region/FragmentBase changeN.SamplesPercent %LCR-HBB/F7\
start at 63,586\
end at 64,134\
3\_ flanking\
sequences\
(enhancer164,081 A \> T homo.67.8%264,081 A \> t het.45.2%363,925C \> A homo.11.3%463,925C \> A het.33.9%563918--63919 -\>C homo ins77100.0%663,923 G \> A het.11.3%763,843 G \> C hom11.3%863,843 G \> C het.33.9%963,818 G \> A het.11.3%1063,826 G \> A het.11.3%

3.2. Relationship between genetic changes identified in beta globin and clinical symptoms in patients {#s0050}
-----------------------------------------------------------------------------------------------------

The clinical symptoms of SCD patients vary from mild symptoms to severe complications that completely change their lifestyle and may even lead to disability from normal life. The changes identified above were correlated with the most frequent biochemical indicators among the surveyed patients to determine the relationship between these changes and the severity of those symptoms.WBC count:

As shown in the [Table 4](#t0020){ref-type="table"}, there was a significant difference between those individuals with LCR \# F1_LCR \# F1_10 mutation and who don't (i.e., those 2 mutations can cause increase of the white blood cell count.Hemoglobin level:Table 4Relationship between WBC count and mutation.Part/VariableWBCMeanMedianStandard DeviationLCR\#F1_2Normal10.8911.054.21Mutated15.6515.203.44LCR\#F1_10Normal10.6611.053.54Mutated18.0116.506.12LCR\#F1_13Normal11.5811.334.41Mutated10.0611.333.90LCR\#F3_9Normal11.5211.194.64Mutated10.8411.333.55

As shown in [Table 5](#t0025){ref-type="table"}, there was no statistical difference between those with mutations, compared to the normal control group.Platelets Count:Table 5Relationship between Hb level and mutation.Part/VariableHB or HgbMeanMedianStandard DeviationLCR\#F1_2Normal91.191.720.9Mutated97.5102.015.7LCR\#F1_10Normal91.091.720.8Mutated98.1106.015.9LCR\#F1_13Normal92.491.719.0Mutated88.091.727.2LCR\#F3_9Normal92.291.722.3Mutated90.291.715.4

As shown in [Table 6](#t0030){ref-type="table"}, there was a significant difference between those with mutations in LCR \# F3_9, compared to the normal control group (i.e., this mutation may cause a decrease in platelets counts).Table 6Relationship between Platelets count and mutation.Part/VariablePltMeanMedianStandard DeviationLCR\#F1_2Normal368362172Mutated368333103LCR\#F1_10Normal378366174Mutated318323104LCR\#F1_13Normal377364169Mutated301315131LCR\#F3_9Normal389379174Mutated299298115

Level of Lactate Dehydrogenase (LDH):

As shown in [Table 7](#t0035){ref-type="table"}, there was no statistical difference between those with mutations, compared to the normal control group.Bilirubin level:Table 7Relationship between LDH level and mutation.Part/VariableLDHMeanMedianStandard DeviationLCR\#F1_2Normal550.6539.3502.5Mutated426.2453.0121.9LCR\#F1_10Normal547.6539.3503.2Mutated455.8453.0119.0LCR\#F1_13Normal560.6539.3516.5Mutated434.1497.0228.7LCR\#F3_9Normal558.7539.3564.8Mutated490.8539.3120.9

As shown in [Table 8](#t0040){ref-type="table"}, there was a significant difference between those with mutation in LCR \# F1_13, compared to normal individuals (i.e, this mutation can increase bilirubin level).Table 8Relationship between Bilirubin level and mutation.Part/ VariableBilirubinMeanMedianStandard DeviationLCR\#F1_2Normal48.148.135.2Mutated48.947.021.5LCR\#F1_10Normal47.548.134.2Mutated55.147.034.9LCR\#F1_13Normal50.848.236.0Mutated35.242.018.0LCR\#F3_9Normal49.248.037.2Mutated45.647.625.1

Using Mann-Whitney test to determine whether there is a relationship between the parameters including: WBC, HB, PLT, LDH, Bilirubin and those individuals with mutations, [Table 9](#t0045){ref-type="table"} showed significant effect of some mutations on those individuals examined Hb, Platelets, and Bilirubin.Table 9Relationship between Lab parameters and presence of mutation(s).Part/VariableSignificance Level (P- Value) one tailWBCHBPLTLDHBilirubinLCR\#F1_20.001 \*0.1000.4370.0650.337LCR\#F1_100.001 \*0.1220.1010.150.257LCR\#F1_130.1940.50.0930.060.048 \*LCR\#F3_90.4950.3280.034 \*0.4480.343

4. Discussion {#s0055}
=============

Analysis of the local control regions (LCR) showed many differences and changes on SCD patients. These changes widely varied among the substitutions within different nitrogen bases. Changes found were either homo or asymmetric. The number of changes identified from SCD patients in local control areas was 69.

[@b0105] reported interesting results that the prevalence of sickle cell anaemia and thalassemia in Al-Qassim region, to be 0.165% and 0.252% respectively. Also showed that the clinical manifestations of sickle cell disease vary widely among patients, where some patients with sickle cell anaemia have mild disease, while others suffer from a severe form and relatively high mortality at early age.

Our current results were obtained from 69 SCD patients at the KKUH from various regions of Saudi Arabia, exhibiting a wide spectrum of the disease from mild to severe stages. This was evidenced by the follow-up of several indicators in patients\' records throughout the study period. The differences in SCD patients were related to the need for medical emergency assistance, as well as the need to stay at the hospital for several days to receive the necessary treatment.

A comprehensive molecular analysis of the nucleotide sequence for six LCR outside the region was performed here, results as shown below: (*LCR--HS1: (HBB-LCR1)*, *LCR--HS2: (HBB-LCR2)*, *LCR--HS3:(HBB-LCR3)*, *G-promoter region: (HBB-LCR5)*, *(AT)x(T)y region: (HBB-LCR6);* and *3\_ flanking; sequences (enhancer): (HBB-LCR7).*

The relationship between clinical symptoms and LCR mutations, showed a close relationship between an increase of WBCs and those changes: (751--752 & change: 805--807 -/c homo ins), in the LCR-HS1 region: (HBB-LCR1). Another relationship between a decrease of platelets and those changes: (8947 A \> T het, in the LCR-HS3) segment: (HBB-LCR3). A third relationship was found between elevated Bilirubin level and (a deletion of 710 A - homo del in LCR-HS1) (HBB-LCR1).

[@b0120] studied forty four Saudi HbS homozygous patients with A haplotype. They found that A11 cases were homozygous for A1 haplotype. Moreover, SPNs in BCL11A and HBS1L-Myb were associated with high HbF ([@b0120]). Tunisian group found four independent regions in LCR Hb beta globin namely: (the 5' region of LCR-HS2 site, the intervening sequence region of two fetal G gamma and A gamma genes and 5' of beta-globin gene. There was a close relationship between high Hb F level and the 5' region of LCR-HS2, which could improve our standing on disease severity ([@b0125]). Two additional studies agreed with the Tunisian's results ([@b0130], [@b0135]).

We published a very recent paper studying the nucleotide sequences and the molecular survey of β-globin gene in Saudi patients from 77 SCD patients. A total of 47 alterations have been recognized. SCD had a negative effect on many organs and outcomes ([@b0140]).

In conclusion, it has been clear that this study has successfully identified LCR mutations for random Saudi patients with SCD. The above results should be taken further to set up management strategies to improve outcomes.
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